Guijosa, A., Tsakmaklis, N., Dhe-Paganon, S., Hatcher, J., Ramírez, A., Pizzarella, D., Kofides, A., Peachey, A., Liu, S., Sun, H., Liu, X., Guerrera, M. L., Branagan, A., Keudell, G. V., Sarosiek, S., Castillo, J., Hunter, Z., Treon, S. (2025). CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenström macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies.. Blood. https://doi.org/10.1182/blood-2025-3611